Vir presents data on CHD, CHB trials at AASLD’s The Liver Meeting

Vir Biotechnology announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential clinical impact that VIR-3434, an investigational monoclonal antibody mAb , and VIR-2218, an investigational small interfering ribonucleic acid siRNA , could have for chronic hepatitis delta CHD and chronic hepatitis B CHB patients at the American Association for the Study of Liver Diseases AASLD The Liver Meeting. These include one late-breaking oral presentation and one late-breaking poster presentation. Initial data to be presented in a late-breaking oral presentation from the ongoing Phase 2 SOLSTICE clinical trial demonstrated that after three subcutaneous doses of either VIR-3434 or VIR-2218 monotherapy, six patients rolled over into combination therapy with VIR-3434 and VIR-2218. Of the five participants receiving combination therapy who have reached Week 12, 100% had HDV RNA less than the lower limit of quantification1 with 80% having undetectable HDV RNA2. “CHD impacts over 12 million people worldwide and approximately 100,000 people here in the United States,” said Phil Pang, M.D., Ph.D., Vir’s Executive Vice President, Chief Medical Officer. Company is also evaluating VIR-3434 as monotherapy given twice monthly as part of the SOLSTICE trial.